{"ticker": {"uuid": "428d3268-e95e-4507-abb1-f58bce42dc91", "symbol": "OTLK", "name": "OUTLOOK THERAPEUTICS INC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "UnitedHealth\u2019s stock rallies on improved outlook for the year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNUFFsZmJxOGo5bWlsUExuOHFVTHJmRnh1ZXJUZ2xRNnB6S0VJNlZRbUZLTkctVGt5T3gyZ0RaeHlhdE5WdjlEX19wbDl3NXN1LTZhYmlMamZ3OXY1Q0RCLUNPVmxYNkhwc05lTURjWkk2NjFGbXFpNjMycDVwcWNMcWhVbzQySEowQ1BLZlFEdWtnQ0dtMmhQR1ViR1JNajg2aDFwdWlR?oc=5", "source_name": "MarketWatch", "published_at": "2026-07-16T10:47:00+00:00", "published_display": "16 Jul 2026 10:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Tightens Range As Traders Watch Support", "summary": "Outlook Therapeutics Inc. (OTLK) stock is experiencing a tightening trading range between the mid-$1.50s and high-$1.70s, signaling consolidation after recent volatility. The company, a clinical-stage biotech, faces significant financial challenges including low revenue, substant", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T17:40:05", "published_display": "15 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Outlook Therapeutics (OTLK.US)$ looks like a cup and handle on the daily ans weekly chart. this should take off soon.", "summary": "An analyst from the moomoo community, \"Empchief,\" observes that Outlook Therapeutics (OTLK.US) displays a \"cup and handle\" pattern on its daily and weekly charts. This technical analysis suggests that the stock is poised for an upward movement in the near future.", "url": "https://www.moomoo.com/community/feed/outlook-therapeutics-otlk-us-looks-like-a-cup-and-handle-116923507802117?chain_id=Name1K9-3FXPhg.1l5fil0&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22www.moomoo.com%2Fstock%2FOTLK-US%2Fcommunity%22%7D", "source_name": "Moomoo", "published_at": "2026-07-15T10:12:43", "published_display": "15 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA", "summary": "Outlook Therapeutics (OTLK) announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA, setting a PDUFA target action date of July 29, 2026. The FDA deemed the resubmission a Class 1 review, focusing on labeling as the fi", "url": "https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-otlk-gets-july-180849785.html", "source_name": "Market source", "published_at": "2026-07-14T19:08:45", "published_display": "14 Jul 2026 19:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Jumps As FDA Accepts ONS-5010 Review And Nasdaq Risk Fades", "summary": "Outlook Therapeutics Inc. (OTLK) saw its stock jump after the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava for wet AMD, setting a PDUFA target date of July 29, 2026. This potential approval would establish the first FDA-approved ophthalmi", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_07_14/", "source_name": "StocksToTrade", "published_at": "2026-07-14T18:12:19", "published_display": "14 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taiwan's second-largest chipmaker starts mass production in Singapore; Citi sees improving outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPblRyV21GSC1RVkpSWloxMUJFdE95Sno3S3V2djk5UVItYnNnM2l4NHRrMDNuR2pjd19FNktPcXdEV29vdVRyOVdWNnNqdFluV2xZWHpqNnN0c21JYkpFRnMwYjNSd0hqWjAzOW45R0dka3pGMU9QNFUwTDlMWDZqT2labGwtbThrR1ljZkloWnV5RW5Na01jTFRxTDFhZzlnQ2xRYWZVNNIBrAFBVV95cUxQb3dsT0pYbEprbEpabzhKakY0SUpERzBqbjhZRkFiZFBoTWlMNGczV0t4WHBlS2dBaG93ckxTZDQtb2M3UHJBR3k3eXlzS2hhd0xXVHZkRUd5TFBPc2NOeG1zYmlEQTdCMF8zYWtac09XOUgwS3FiMmVuTFFnYmZ4OExWaXBJWl95czBOS3RzT2hjcm1pdjg5dERUNGt5SDR4Rm1GYm9PVmFRRUtr?oc=5", "source_name": "CNBC", "published_at": "2026-07-14T05:44:04+00:00", "published_display": "14 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Outlook Therapeutics Stock (OTLK) Opinions on Phase 3 Advancement", "summary": "This article discusses Outlook Therapeutics' stock stability and analyzes the company's recent movement in shares after its ONS-5010 (Lytenava) received positive feedback from the FDA regarding its biologics license application. The article provides insights into the company's fi", "url": "https://www.moomoo.com/news/post/72808191/outlook-therapeutics-stock-otlk-opinions-on-phase-3-advancement", "source_name": "Moomoo", "published_at": "2026-07-12T20:41:31", "published_display": "12 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q3 Stock Market Outlook: Investors Face Balanced Risks, Selective Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQZ0tMb25qeWJ6bUx0ckNlTEFFeU5LU0JWT0R0aWdUUlh4VF9sUnZEWWJLUFBBai05U21fbFRJanRjZTM1NmRlMEVqcHItWDl2Vk1mTEJ1TkduVHgySlFzczRIbHpSdV9QMDR3RnIwOUlvQ3A1azM2U3hicFJyM3R3TmVydEFrNjVjMTJHWGc4MG9fakhYNHdKUXh6N29QM2REb21icUMtam1TNVczZUEtajNpbw?oc=5", "source_name": "Morningstar", "published_at": "2026-07-08T16:54:15+00:00", "published_display": "08 Jul 2026 16:54", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Holds Nasdaq Compliance As FDA Clock Starts", "summary": "Outlook Therapeutics Inc. (OTLK) stock has seen a 14.73% increase due to positive news regarding its eye-treatment pipeline. The FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, setting a PDUFA target date of July 29, 2026. Additionally, OTL", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_07_08/", "source_name": "StocksToTrade", "published_at": "2026-07-08T16:33:00", "published_display": "08 Jul 2026 16:33", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics | D: Filing D", "summary": "This article provides a brief notification regarding Outlook Therapeutics, indicating a \"Filing D\" document has been reported. The content provided is minimal, only stating \"Document.\"", "url": "https://www.moomoo.com/news/notice/307246946/outlook-therapeutics-d-filing-d", "source_name": "Moomoo", "published_at": "2026-07-08T07:11:34", "published_display": "08 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Outlook Therapeutics, Inc. \u2013 NASDAQ:OTLK", "summary": "This page from TradingView displays information regarding the enterprise value to revenue for Outlook Therapeutics, Inc. (NASDAQ: OTLK). It highlights the company's financial data within the health technology and pharmaceuticals sector. The content primarily focuses on the financ", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:09:18", "published_display": "04 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava", "summary": "Outlook Therapeutics (OTLK) has regained Nasdaq listing compliance and is expanding its pipeline with multiple Phase 3 ophthalmology programs. The company's stock is under close watch ahead of the scheduled July 29 FDA review of its biologics license application for ONS-5010, whi", "url": "https://www.quiverquant.com/news/Outlook+Therapeutics+Stock+%28OTLK%29+Opinions+on+FDA+Review+for+Lytenava", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T17:57:00", "published_display": "01 Jul 2026 17:57", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Regains Nasdaq Compliance", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/outlook-therapeutics-regains-nasdaq-compliance-141910541.html", "source_name": "MT Newswires", "published_at": "2026-06-29T14:19:10+00:00", "published_display": "29 Jun 2026 14:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "These 3 Stocks Led Wall Street\u2019s Biggest Gains On Tuesday \u2013 Here\u2019s Why", "summary": "Redwire (RDW), T1 Energy (TE), and Outlook Therapeutics (OTLK) shares experienced significant gains on Tuesday, driven by various factors. RDW benefited from optimism in the space sector following SpaceX's impending market debut, while TE soared due to strong institutional backin", "url": "https://stocktwits.com/news-articles/markets/equity/why-rdw-te-otlk-stocks-posted-double-digit-gains-on-tuesday/cZgXzBfReA9", "source_name": "Stocktwits", "published_at": "2026-06-27T18:10:31", "published_display": "27 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK - Outlook Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Outlook Therapeutics Inc. (OTLK), along with a comprehensive overview of its financial performance, key statistical data, and market metrics. It includes details such as stock performance, analyst recommendations, and in", "url": "https://finviz.com/stock?t=OTLK&p=d&ty=lf&page=10", "source_name": "Finviz", "published_at": "2026-06-27T16:11:07", "published_display": "27 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) restores Nasdaq minimum bid compliance, delisting threat closed", "summary": "Outlook Therapeutics (OTLK) has successfully regained compliance with Nasdaq's minimum bid price requirement, effectively closing the delisting threat. The company's common stock traded at or above $1.00 per share for ten consecutive business days, satisfying Nasdaq Listing Rule ", "url": "https://www.stocktitan.net/sec-filings/OTLK/8-k-outlook-therapeutics-inc-reports-material-event-1b8765536248.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:10:08", "published_display": "26 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Outlook Therapeutics (OTLK) announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) regarding a minimum bid price. The company's closing bid price was at or above $1.00 for ten consecutive business days from June 11\u201325, 2026, leading Nasdaq to close the ma", "url": "https://www.tradingview.com/news/tradingview:35387ecfbb645:0-outlook-therapeutics-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:08", "published_display": "26 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Outlook Therapeutics, Inc. \u2013 NASDAQ:OTLK", "summary": "This article provides an \"Enterprise value to EBITDA forward\" metric for Outlook Therapeutics, Inc. (NASDAQ: OTLK). The content appears to be a financial data snippet from TradingView, indicating the value and changes for this specific financial ratio for the company. The article", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:08", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Climbs As FDA Fast-Tracks Lytenava Decision", "summary": "Outlook Therapeutics Inc. (OTLK) stock climbed 8.7% after the FDA accepted its Biologics License Application (BLA) for ONS-5010/Lytenava as a Class 1 review, with a target decision date of July 29, 2026. The FDA's Office of New Drugs has found substantial evidence of effectivenes", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_06_26/", "source_name": "StocksToTrade", "published_at": "2026-06-26T12:33:00", "published_display": "26 Jun 2026 12:33", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics, Inc. Actuals & Estimates (NASDAQ:OTLK)", "summary": "This article provides a comprehensive overview of Outlook Therapeutics, Inc. (OTLK) stock, including historical data, analyst forecasts, and financial performance. It covers various metrics such as current stock price, market capitalization, earnings, revenue, and future earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:15", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Outlook Therapeutics, Inc. \u2013 MUN:41O", "summary": "This article concerns the enterprise value to revenue dynamics for Outlook Therapeutics, Inc. (MUN:41O) on the Munich Stock Exchange. The content is primarily a placeholder from TradingView, offering no specific financial data or analysis beyond the initial statement of the topic", "url": "https://www.tradingview.com/symbols/MUN-41O/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:41:08", "published_display": "25 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Outlook Therapeutics, Inc. \u2013 NASDAQ:OTLK", "summary": "This article provides the \"Price to sales forward\" financial metric for Outlook Therapeutics, Inc. (NASDAQ: OTLK). It highlights the company's financial data as presented on TradingView, a financial charting and analysis platform. The content is primarily a data point for investo", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:08", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis", "summary": "Outlook Therapeutics Inc (OTLK) currently holds a valuation score of 9.14, placing it 57th out of 388 companies in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.49, which is significantly lower than its recent high but higher than its recent low. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-otlk/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-25T10:40:18", "published_display": "25 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Outlook Therapeutics, Inc. \u2013 MUN:41O", "summary": "This article displays financial data for Outlook Therapeutics, Inc. (MUN:41O), specifically its \"Price to book forward\" metric. The content is presented within the TradingView platform interface, indicating a focus on financial analysis and market information for the pharmaceutic", "url": "https://www.tradingview.com/symbols/MUN-41O/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T07:40:18", "published_display": "25 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News", "summary": "This document, titled \"Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News,\" is an empty placeholder. It indicates the subject matter relates to Outlook Therapeutics (OTLK) stock options, quotes, and news, but no content is provided.", "url": "https://www.moomoo.com/stock/OTLK-US/options-chain?chain_id=Name1K9-3FXPhg.1kvnlg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2F7134-BMS%2Ffinancials-income-statement%22%7D", "source_name": "Moomoo", "published_at": "2026-06-22T01:10:52", "published_display": "22 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision", "summary": "Outlook Therapeutics (OTLK) saw its stock jump 28% after the FDA accepted its resubmitted biologics license application for LYTENAVA, setting a decision date of July 29, 2026. The drug, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab for wet age", "url": "https://stocktwits.com/news-articles/markets/equity/otlk-stock-soars-after-fda-sets-july-date-for-lytenava-decision/cZKWxhdR741", "source_name": "Stocktwits", "published_at": "2026-06-18T09:40:39", "published_display": "18 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review", "summary": "Shares of Outlook Therapeutics (OTLK) surged 35.3% after the FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, its wet AMD treatment. The FDA classified it as a Class 1 resubmission with a decision date of July 29, 2026, marking the final sta", "url": "https://www.tradingview.com/news/zacks:5bfdcdac2094b:0-otlk-stock-up-35-as-fda-accepts-resubmitted-eye-drug-bla-for-review/", "source_name": "TradingView", "published_at": "2026-06-17T14:38:55", "published_display": "17 Jun 2026 14:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA sets July 29, 2026 PDUFA date for Outlook Therapeutics (OTLK) ONS-5010 BLA", "summary": "Outlook Therapeutics announced that the FDA has acknowledged its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration. The resubmission was classified as a Class 1 review, leading to a 60-day review period and", "url": "https://www.stocktitan.net/sec-filings/OTLK/8-k-outlook-therapeutics-inc-reports-material-event-c6373949e5ec.html", "source_name": "Stock Titan", "published_at": "2026-06-17T11:40:57", "published_display": "17 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts resubmitted BLA from Outlook Therapeutics", "summary": "Outlook Therapeutics saw its shares climb over 25% after the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava. This treatment is intended for age-related macular degeneration (AMD), and the FDA has designated it a Class 1 review with a target", "url": "https://www.thepharmaletter.com/biotech-news/fda-accepts-resubmitted-bla-from-outlook-therapeutics", "source_name": "The Pharma Letter", "published_at": "2026-06-17T09:38:55", "published_display": "17 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Gains FDA Acknowledgment for BLA Resubmission", "summary": "Outlook Therapeutics (OTLK) announced that the FDA has acknowledged the resubmission of its biologics license application (BLA) for ONS-5010 (Lytenava) to treat wet age-related macular degeneration, classifying it as a Class 1 review with a target action date of July 29, 2026. De", "url": "https://www.gurufocus.com/news/8918614/outlook-therapeutics-otlk-gains-fda-acknowledgment-for-bla-resubmission?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-16T22:38:55", "published_display": "16 Jun 2026 22:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms", "summary": "Outlook Therapeutics' stock surged by about 30% after the FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration, with a PDUFA date set for July 29, 2026. This acceptance provides a clearer regulatory path, but the company sti", "url": "https://ts2.tech/en/outlook-therapeutics-stock-jumps-as-fda-accepts-lytenava-bla-july-decision-looms/", "source_name": "TechStock\u00b2", "published_at": "2026-06-16T20:09:14", "published_display": "16 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics stock surges on FDA BLA resubmission", "summary": "Outlook Therapeutics Inc. (NASDAQ:OTLK) shares rose after the FDA accepted its resubmitted Biologics License Application for ONS-5010/LYTENAVA, aimed at treating wet age-related macular degeneration. The FDA has set a target action date of July 29, 2026, for this Class 1 review. ", "url": "https://www.investing.com/news/stock-market-news/outlook-therapeutics-stock-surges-on-fda-bla-resubmission-93CH-4745082", "source_name": "Investing.com", "published_at": "2026-06-16T14:09:14", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 93, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Announces FDA Acceptance of Resubmitted BLA for ONS-5010", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-announces-fda-acceptance-123508638.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:35:08+00:00", "published_display": "16 Jun 2026 12:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics: FDA accepts resubmitted BLA for ONS-5010 with PDUFA date July 29, 2026", "summary": "Outlook Therapeutics announced that the FDA has accepted its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) for the treatment of wet Age-related Macular Degeneration (AMD). The FDA has designated this resubmission for a Class 1 review, setting a P", "url": "https://www.tradingview.com/news/tradingview:bd8a65baecb83:0-outlook-therapeutics-fda-accepts-resubmitted-bla-for-ons-5010-with-pdufa-date-july-29-2026/", "source_name": "TradingView", "published_at": "2026-06-16T13:09:14", "published_display": "16 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA\u2122 (bevacizumab-vikg) as a Treatment for Wet AMD", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-announces-fda-acceptance-120200927.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T12:02:00+00:00", "published_display": "16 Jun 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPTkVRLVQyZzB6WkhKRzV0bXNicUpBbjNjMW5DUUc4TENoRUpnNGdpQkVxNmdGbU5sd205c25LZWRMWW44WGVrejliZkFlS192OUo0OGVrTDBseklWNk92SGRHQXgwN1N4Rnp4TmVHcnNEdFlLYTdVXzQ1dkNqTE94S2RjUUc5NlE0UERFOW5OY3lFamRzRWJSR1N2alU?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Announces FDA Acceptance of", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxQUzB4OVZEUzA1QXdtZllGZUtDU0RWeTJVR05pcmpMZVhHOFU4UjJjZnl3V1NidDJsdW05LS1QZEVHWFhKZnRSekVCTWdTaVEtTnBCRHZrTnVPb0hhRjlsV0RrVkNiTVRXb1E5QkFkRkRmbk8tZkowSUY3Yk5pVU1YYU5ibEZVVERXd2JkYlBhU3JibGZaWDN4bW1KMWhlUkcyd2k5T3hKMHJrVWp5anBERmF4VVFUUlRGYkFlV0FUczNhY05vRkNkUERpT0c0ZU5lVXcydUFJdmJ5b1YyeGhjLUJISVIwbHJuN3E1M1ZrVmd3U0haWS00eVQ2OFpZb256bG91TGozS1M4b1R1bUZ1N0w2UFZxNExCWXNNNjFIVUZpQ3RZaXI1UmRnZ0YzMlpZbC1vUUFfRW1PLUpScnZCMFRjMU41RWg2RGtsSQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Is Up 60.7% After FDA Class 1 Review Acceptance For Lytenava", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNUWdyS01vWE5rLUxwR1hYa3Z0T2pONmlMSmRxZW01MUJIT09NUVhDRXFJMmJUZVk0ZWl2eDdmT192ZDhoTC15ajUzT1RkQ29kNk9CYmVMc2lnTzhGNlBpVzh5OEVjdFRfdmVNbXZ2VUNfYURKSXlTX1FIYV9zYTZkNFpLdkdzT2pzODZLdnhfd2RSZmJxVEVSWm1jcWFlUHlfT1NR?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Stock After FDA Class 1 BLA Resubmission Is The Valuation Out Of Line", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQVlNFdXdmcDUxdF9yTHByaEVqTTRCbkM3akNmTldoZXdkNEt3eTVldXRSWEdnM2Z5Um1uTHN3S2EwVzVjWHhycWQ0cVJybGdyd19DUXpvWmVJSVg2bTdXYksxTHBWZWl3dEx3bHRoRk83X2J3WGstUkh6UV9oNUlwRWkySEwyMW5uUllSdHVSdE5oSDI5cGloV2lnd0JUWWVDdDRjdWtCcUNoZnpGQlBKYmphbHRLZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/outlook-therapeutics-resubmits-lytenava-biologics-131622271.html", "source_name": "MT Newswires", "published_at": "2026-06-01T13:16:22+00:00", "published_display": "01 Jun 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPcTNvcTl0T0djVzlvdVhUZU5qNkwwTmJ6RlZDcVNZUkJ1eXFhNGlZTTdHNmtzbGo5N1JxSWUtT21LelB2MzNfUUN6d1RZM1BmdUpkQ19zWHJkNXRpWXVvTFR6M0dBazFMUmQ0S3NHUk1sT1kxRDl1akdzWm1XZTg1RTExUWtGSXQ5bUoteThuYWlrY0pNa3lOTVlBZ2RacFBMU1h1R2tIZ19ZSXdmYk1QNHpfLWQ?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (Nasdaq: OTLK) resubmits FDA BLA with 60-day review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOYW9vTU5FT0hqUzFzQUFWdzVFMFRrUTg1T0Mwb20zOEJZcGxEcldKUnNMU3FhZGhHaGlVNzlOUklBdGlxNHJfNHZ2dkdWdDJaNFVsZzlwclZtZUZNSk52T21jOTRfRVpWdFh4bG1hZUs2cHk5VTQ5Ni1rTTBTNlNFMDd3a3ZEQ0JzZHBKN0xTTHdGTTVBb3IzVG5MVDNvZ21JZ2hibzBoQ2NuWi1fTlZ2TW9VSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (NASDAQ: OTLK) amends warrants and sells 8.54M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOSGFqQ3dkMFlzYkg5VG42S1AyM3NJMmNDZFFwOXlkcW5yY2FNLUtNVzl3TnFzeUEydW81WjJId0l1a19XWkFoUl9IUEZKRFh3TkVLc0JaYUZhdjZSQUpLVFktelpGMV9CcVN3MUZudlkySmREa2hoUzB4bFFPcnV4OGxmeUI3eVYycVNueGZaNzJ2YXQyLThSYnBTX08wRFFpMjdnNWRUOFBHZzhPeXJibmZlWEFwS0NYNUtjcnRRWjdZSExBYXB2V3l3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics raises $5M from top holder, cuts warrant price to $0.5855", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQRlJpZzFvcXFEZEpQamp6TTVZVHpZLXk5VUhfSDZaa2Q5V0x1Zjh3Vm9oeGRRcFpNamtUUGFQajB1a3ctdXJMbnU2eGQ2ZFNldFZVczlRLVJPNHpRQjFFZ1JvMXYzM0xLWU9sRkR0Y05TcUdiNGN4VHhHV2d4NURYVWljLWdxQnZwRmdOQm0wdHZfSkZITUlyRmpGTVJCV2I1Qm05SXdpWkVyeF83Rkk5YWxtQU9iVTBhNTBr?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA\u2122 (bevacizumab-vikg)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNUXcwMlhPQVh4T0Nha1F4c3dGSm9ZM2VMTEpVWnZ5SzU3NzQ2dnJxX2paQ3ZjT0xqU004VUZhSkxueFJxX294Zlo2T2RaOW5GQjNqM1diclNTTHNHUENyUHlDdjlxbE1aMWdEeU9jZDd6TlBLQ2N2ZHR1Z1FpTG5zRUNlc0prNHNyMWIyYzYtNWpoY0hfQTRBc3JPVTAxMWVNSlNlT1dSdWVfeEtOT2I3ZA?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Reports Second Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNaVU5NkxxQmpVcTNvTG1EQkF4alk2VXFEencyY2Itdm9VUFF5bHhzNE5XbC0xbjVDVTJlV0h0VGVTT3hobGVjMkdqQ0xHYmFxYndCQ0V5Mzh2WmZCTC1ERnBDUTNWRFpna21CLXhPY1FFOU1GOFdyNGRVUkp1QnVMMFREclc4bVA4V1l3cENUeVBlRy1VSGhaM25vZXZ4TUMxMC1LYVBoWkk0RXV6MjVMZnVDcw?oc=5", "source_name": "VisionMonday.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxPYV8wZlE5Yl82Um9POEgzcVVxNE8xZ2JzTzNwQXkwZm9lOE5xVnI4Q3VLV0pqVHdac2gzbjFPV1VfclJCMGJidTFYZEg5UkxxVWVGY0NuQzZwb3NfRzFaLVJBOTAteDF2aml1OHJmOXhUR3A4dGpzN2ZCbFJJRHRZVEF3dlRkSk1NNkZhcXl3TzRJbXNDRUZVMXhFZ2ZFeXFyVE10MWUxS3ZmMDAzYm9sRmZlSFBKMUlhS3NzdlpkcDVvQkpjX3BCT3ExZmFIM1ZFY1RSOUZiaV9JamxSS1lwYThrVlA1UHd3M3VCV2JPRllBNmxQSjN6QmVYcVRXMXA4TEZKYlhuZUFiMXg2?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Outlook Therapeutics files dispute resolution request with FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUWplNmg3aldZSk5OOFJJRDRWT3FfQVBjWThlVDhDZG5MVkUyWEhtMHBEZ2dBeVlMbDFlaXJLQjhITW1wSDhPdExuOFp4LW9HNnE4X19nVFhYUGdhOWRHWlk3WXczdEN0S0Vvd3F0aGhES2NQQTJNYndPX2VwUEdZYnhfRW94enI3Vm5PRGp2ZmtYTHdsN21ZTUpodTVOZHcyTFBSX0p6dG9HR21JQk9IMDYxRV9jYnc5WUhN?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA\u2122 (bevacizumab-vikg) for the Treatment of Wet AMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPUWk4LXBvLWE1YmhMcXctTXZQVi1tWjRMZWdWdndrbmtVS2F6X1Z2ZTZ2NDBOSXc5ckVMTlAyNmNsWm1PZmNZTGp0dGs3QUxVREtNcGZKM0syYVdOSjFnQ01hY1pBR0R5TUVRVjMyMnZ6eFJMUnhqMm5VekZaeTg1SlowYXVkNjZSZzEyMjhGQ19hQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "UnitedHealth\u2019s stock rallies on improved outlook for the year", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNUFFsZmJxOGo5bWlsUExuOHFVTHJmRnh1ZXJUZ2xRNnB6S0VJNlZRbUZLTkctVGt5T3gyZ0RaeHlhdE5WdjlEX19wbDl3NXN1LTZhYmlMamZ3OXY1Q0RCLUNPVmxYNkhwc05lTURjWkk2NjFGbXFpNjMycDVwcWNMcWhVbzQySEowQ1BLZlFEdWtnQ0dtMmhQR1ViR1JNajg2aDFwdWlR?oc=5", "source_name": "MarketWatch", "published_at": "2026-07-16T10:47:00+00:00", "published_display": "16 Jul 2026 10:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Tightens Range As Traders Watch Support", "summary": "Outlook Therapeutics Inc. (OTLK) stock is experiencing a tightening trading range between the mid-$1.50s and high-$1.70s, signaling consolidation after recent volatility. The company, a clinical-stage biotech, faces significant financial challenges including low revenue, substant", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T17:40:05", "published_display": "15 Jul 2026 17:40", "sentiment": "negative", "sentiment_pct": 26, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$Outlook Therapeutics (OTLK.US)$ looks like a cup and handle on the daily ans weekly chart. this should take off soon.", "summary": "An analyst from the moomoo community, \"Empchief,\" observes that Outlook Therapeutics (OTLK.US) displays a \"cup and handle\" pattern on its daily and weekly charts. This technical analysis suggests that the stock is poised for an upward movement in the near future.", "url": "https://www.moomoo.com/community/feed/outlook-therapeutics-otlk-us-looks-like-a-cup-and-handle-116923507802117?chain_id=Name1K9-3FXPhg.1l5fil0&global_content=%7B%22promote_id%22%3A13764%2C%22sub_promote_id%22%3A57%2C%22f%22%3A%22www.moomoo.com%2Fstock%2FOTLK-US%2Fcommunity%22%7D", "source_name": "Moomoo", "published_at": "2026-07-15T10:12:43", "published_display": "15 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 77, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Gets July 29 PDUFA Date for LYTENAVA", "summary": "Outlook Therapeutics (OTLK) announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for ONS-5010/LYTENAVA, setting a PDUFA target action date of July 29, 2026. The FDA deemed the resubmission a Class 1 review, focusing on labeling as the fi", "url": "https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-otlk-gets-july-180849785.html", "source_name": "Market source", "published_at": "2026-07-14T19:08:45", "published_display": "14 Jul 2026 19:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Jumps As FDA Accepts ONS-5010 Review And Nasdaq Risk Fades", "summary": "Outlook Therapeutics Inc. (OTLK) saw its stock jump after the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava for wet AMD, setting a PDUFA target date of July 29, 2026. This potential approval would establish the first FDA-approved ophthalmi", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_07_14/", "source_name": "StocksToTrade", "published_at": "2026-07-14T18:12:19", "published_display": "14 Jul 2026 18:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Taiwan's second-largest chipmaker starts mass production in Singapore; Citi sees improving outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPblRyV21GSC1RVkpSWloxMUJFdE95Sno3S3V2djk5UVItYnNnM2l4NHRrMDNuR2pjd19FNktPcXdEV29vdVRyOVdWNnNqdFluV2xZWHpqNnN0c21JYkpFRnMwYjNSd0hqWjAzOW45R0dka3pGMU9QNFUwTDlMWDZqT2labGwtbThrR1ljZkloWnV5RW5Na01jTFRxTDFhZzlnQ2xRYWZVNNIBrAFBVV95cUxQb3dsT0pYbEprbEpabzhKakY0SUpERzBqbjhZRkFiZFBoTWlMNGczV0t4WHBlS2dBaG93ckxTZDQtb2M3UHJBR3k3eXlzS2hhd0xXVHZkRUd5TFBPc2NOeG1zYmlEQTdCMF8zYWtac09XOUgwS3FiMmVuTFFnYmZ4OExWaXBJWl95czBOS3RzT2hjcm1pdjg5dERUNGt5SDR4Rm1GYm9PVmFRRUtr?oc=5", "source_name": "CNBC", "published_at": "2026-07-14T05:44:04+00:00", "published_display": "14 Jul 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Stock (OTLK) Opinions on Phase 3 Advancement", "summary": "This article discusses Outlook Therapeutics' stock stability and analyzes the company's recent movement in shares after its ONS-5010 (Lytenava) received positive feedback from the FDA regarding its biologics license application. The article provides insights into the company's fi", "url": "https://www.moomoo.com/news/post/72808191/outlook-therapeutics-stock-otlk-opinions-on-phase-3-advancement", "source_name": "Moomoo", "published_at": "2026-07-12T20:41:31", "published_display": "12 Jul 2026 20:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q3 Stock Market Outlook: Investors Face Balanced Risks, Selective Opportunities", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQZ0tMb25qeWJ6bUx0ckNlTEFFeU5LU0JWT0R0aWdUUlh4VF9sUnZEWWJLUFBBai05U21fbFRJanRjZTM1NmRlMEVqcHItWDl2Vk1mTEJ1TkduVHgySlFzczRIbHpSdV9QMDR3RnIwOUlvQ3A1azM2U3hicFJyM3R3TmVydEFrNjVjMTJHWGc4MG9fakhYNHdKUXh6N29QM2REb21icUMtam1TNVczZUEtajNpbw?oc=5", "source_name": "Morningstar", "published_at": "2026-07-08T16:54:15+00:00", "published_display": "08 Jul 2026 16:54", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Holds Nasdaq Compliance As FDA Clock Starts", "summary": "Outlook Therapeutics Inc. (OTLK) stock has seen a 14.73% increase due to positive news regarding its eye-treatment pipeline. The FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, setting a PDUFA target date of July 29, 2026. Additionally, OTL", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_07_08/", "source_name": "StocksToTrade", "published_at": "2026-07-08T16:33:00", "published_display": "08 Jul 2026 16:33", "sentiment": "positive", "sentiment_pct": 67, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics | D: Filing D", "summary": "This article provides a brief notification regarding Outlook Therapeutics, indicating a \"Filing D\" document has been reported. The content provided is minimal, only stating \"Document.\"", "url": "https://www.moomoo.com/news/notice/307246946/outlook-therapeutics-d-filing-d", "source_name": "Moomoo", "published_at": "2026-07-08T07:11:34", "published_display": "08 Jul 2026 07:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Outlook Therapeutics, Inc. \u2013 NASDAQ:OTLK", "summary": "This page from TradingView displays information regarding the enterprise value to revenue for Outlook Therapeutics, Inc. (NASDAQ: OTLK). It highlights the company's financial data within the health technology and pharmaceuticals sector. The content primarily focuses on the financ", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:09:18", "published_display": "04 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Stock (OTLK) Opinions on FDA Review for Lytenava", "summary": "Outlook Therapeutics (OTLK) has regained Nasdaq listing compliance and is expanding its pipeline with multiple Phase 3 ophthalmology programs. The company's stock is under close watch ahead of the scheduled July 29 FDA review of its biologics license application for ONS-5010, whi", "url": "https://www.quiverquant.com/news/Outlook+Therapeutics+Stock+%28OTLK%29+Opinions+on+FDA+Review+for+Lytenava", "source_name": "Quiver Quantitative", "published_at": "2026-07-01T17:57:00", "published_display": "01 Jul 2026 17:57", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Regains Nasdaq Compliance", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/outlook-therapeutics-regains-nasdaq-compliance-141910541.html", "source_name": "MT Newswires", "published_at": "2026-06-29T14:19:10+00:00", "published_display": "29 Jun 2026 14:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "These 3 Stocks Led Wall Street\u2019s Biggest Gains On Tuesday \u2013 Here\u2019s Why", "summary": "Redwire (RDW), T1 Energy (TE), and Outlook Therapeutics (OTLK) shares experienced significant gains on Tuesday, driven by various factors. RDW benefited from optimism in the space sector following SpaceX's impending market debut, while TE soared due to strong institutional backin", "url": "https://stocktwits.com/news-articles/markets/equity/why-rdw-te-otlk-stocks-posted-double-digit-gains-on-tuesday/cZgXzBfReA9", "source_name": "Stocktwits", "published_at": "2026-06-27T18:10:31", "published_display": "27 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK - Outlook Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Outlook Therapeutics Inc. (OTLK), along with a comprehensive overview of its financial performance, key statistical data, and market metrics. It includes details such as stock performance, analyst recommendations, and in", "url": "https://finviz.com/stock?t=OTLK&p=d&ty=lf&page=10", "source_name": "Finviz", "published_at": "2026-06-27T16:11:07", "published_display": "27 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) restores Nasdaq minimum bid compliance, delisting threat closed", "summary": "Outlook Therapeutics (OTLK) has successfully regained compliance with Nasdaq's minimum bid price requirement, effectively closing the delisting threat. The company's common stock traded at or above $1.00 per share for ten consecutive business days, satisfying Nasdaq Listing Rule ", "url": "https://www.stocktitan.net/sec-filings/OTLK/8-k-outlook-therapeutics-inc-reports-material-event-1b8765536248.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:10:08", "published_display": "26 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard", "summary": "Outlook Therapeutics (OTLK) announced that it has regained compliance with Nasdaq's Listing Rule 5550(a)(2) regarding a minimum bid price. The company's closing bid price was at or above $1.00 for ten consecutive business days from June 11\u201325, 2026, leading Nasdaq to close the ma", "url": "https://www.tradingview.com/news/tradingview:35387ecfbb645:0-outlook-therapeutics-disclosed-failure-to-satisfy-a-continued-listing-rule-or-standard/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:08", "published_display": "26 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Outlook Therapeutics, Inc. \u2013 NASDAQ:OTLK", "summary": "This article provides an \"Enterprise value to EBITDA forward\" metric for Outlook Therapeutics, Inc. (NASDAQ: OTLK). The content appears to be a financial data snippet from TradingView, indicating the value and changes for this specific financial ratio for the company. The article", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:10:08", "published_display": "26 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Climbs As FDA Fast-Tracks Lytenava Decision", "summary": "Outlook Therapeutics Inc. (OTLK) stock climbed 8.7% after the FDA accepted its Biologics License Application (BLA) for ONS-5010/Lytenava as a Class 1 review, with a target decision date of July 29, 2026. The FDA's Office of New Drugs has found substantial evidence of effectivenes", "url": "https://stockstotrade.com/news/outlook-therapeutics-inc-otlk-news-2026_06_26/", "source_name": "StocksToTrade", "published_at": "2026-06-26T12:33:00", "published_display": "26 Jun 2026 12:33", "sentiment": "positive", "sentiment_pct": 76, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics, Inc. Actuals & Estimates (NASDAQ:OTLK)", "summary": "This article provides a comprehensive overview of Outlook Therapeutics, Inc. (OTLK) stock, including historical data, analyst forecasts, and financial performance. It covers various metrics such as current stock price, market capitalization, earnings, revenue, and future earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:10:15", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Outlook Therapeutics, Inc. \u2013 MUN:41O", "summary": "This article concerns the enterprise value to revenue dynamics for Outlook Therapeutics, Inc. (MUN:41O) on the Munich Stock Exchange. The content is primarily a placeholder from TradingView, offering no specific financial data or analysis beyond the initial statement of the topic", "url": "https://www.tradingview.com/symbols/MUN-41O/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T17:41:08", "published_display": "25 Jun 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Outlook Therapeutics, Inc. \u2013 NASDAQ:OTLK", "summary": "This article provides the \"Price to sales forward\" financial metric for Outlook Therapeutics, Inc. (NASDAQ: OTLK). It highlights the company's financial data as presented on TradingView, a financial charting and analysis platform. The content is primarily a data point for investo", "url": "https://www.tradingview.com/symbols/NASDAQ-OTLK/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T15:41:08", "published_display": "25 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis", "summary": "Outlook Therapeutics Inc (OTLK) currently holds a valuation score of 9.14, placing it 57th out of 388 companies in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.49, which is significantly lower than its recent high but higher than its recent low. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-otlk/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-25T10:40:18", "published_display": "25 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Outlook Therapeutics, Inc. \u2013 MUN:41O", "summary": "This article displays financial data for Outlook Therapeutics, Inc. (MUN:41O), specifically its \"Price to book forward\" metric. The content is presented within the TradingView platform interface, indicating a focus on financial analysis and market information for the pharmaceutic", "url": "https://www.tradingview.com/symbols/MUN-41O/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T07:40:18", "published_display": "25 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News", "summary": "This document, titled \"Outlook Therapeutics(OTLK) Stock Options Chain | Quotes & News,\" is an empty placeholder. It indicates the subject matter relates to Outlook Therapeutics (OTLK) stock options, quotes, and news, but no content is provided.", "url": "https://www.moomoo.com/stock/OTLK-US/options-chain?chain_id=Name1K9-3FXPhg.1kvnlg0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A57,%22f%22%3A%22www.moomoo.com%2Fhant%2Fstock%2F7134-BMS%2Ffinancials-income-statement%22%7D", "source_name": "Moomoo", "published_at": "2026-06-22T01:10:52", "published_display": "22 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision", "summary": "Outlook Therapeutics (OTLK) saw its stock jump 28% after the FDA accepted its resubmitted biologics license application for LYTENAVA, setting a decision date of July 29, 2026. The drug, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab for wet age", "url": "https://stocktwits.com/news-articles/markets/equity/otlk-stock-soars-after-fda-sets-july-date-for-lytenava-decision/cZKWxhdR741", "source_name": "Stocktwits", "published_at": "2026-06-18T09:40:39", "published_display": "18 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review", "summary": "Shares of Outlook Therapeutics (OTLK) surged 35.3% after the FDA accepted the resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava, its wet AMD treatment. The FDA classified it as a Class 1 resubmission with a decision date of July 29, 2026, marking the final sta", "url": "https://www.tradingview.com/news/zacks:5bfdcdac2094b:0-otlk-stock-up-35-as-fda-accepts-resubmitted-eye-drug-bla-for-review/", "source_name": "TradingView", "published_at": "2026-06-17T14:38:55", "published_display": "17 Jun 2026 14:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA sets July 29, 2026 PDUFA date for Outlook Therapeutics (OTLK) ONS-5010 BLA", "summary": "Outlook Therapeutics announced that the FDA has acknowledged its resubmitted Biologics License Application (BLA) for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration. The resubmission was classified as a Class 1 review, leading to a 60-day review period and", "url": "https://www.stocktitan.net/sec-filings/OTLK/8-k-outlook-therapeutics-inc-reports-material-event-c6373949e5ec.html", "source_name": "Stock Titan", "published_at": "2026-06-17T11:40:57", "published_display": "17 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA accepts resubmitted BLA from Outlook Therapeutics", "summary": "Outlook Therapeutics saw its shares climb over 25% after the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/Lytenava. This treatment is intended for age-related macular degeneration (AMD), and the FDA has designated it a Class 1 review with a target", "url": "https://www.thepharmaletter.com/biotech-news/fda-accepts-resubmitted-bla-from-outlook-therapeutics", "source_name": "The Pharma Letter", "published_at": "2026-06-17T09:38:55", "published_display": "17 Jun 2026 09:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Gains FDA Acknowledgment for BLA Resubmission", "summary": "Outlook Therapeutics (OTLK) announced that the FDA has acknowledged the resubmission of its biologics license application (BLA) for ONS-5010 (Lytenava) to treat wet age-related macular degeneration, classifying it as a Class 1 review with a target action date of July 29, 2026. De", "url": "https://www.gurufocus.com/news/8918614/outlook-therapeutics-otlk-gains-fda-acknowledgment-for-bla-resubmission?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-16T22:38:55", "published_display": "16 Jun 2026 22:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Stock Jumps as FDA Accepts Lytenava BLA, July Decision Looms", "summary": "Outlook Therapeutics' stock surged by about 30% after the FDA accepted its resubmitted BLA for ONS-5010/LYTENAVA, a treatment for wet age-related macular degeneration, with a PDUFA date set for July 29, 2026. This acceptance provides a clearer regulatory path, but the company sti", "url": "https://ts2.tech/en/outlook-therapeutics-stock-jumps-as-fda-accepts-lytenava-bla-july-decision-looms/", "source_name": "TechStock\u00b2", "published_at": "2026-06-16T20:09:14", "published_display": "16 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 69, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics stock surges on FDA BLA resubmission", "summary": "Outlook Therapeutics Inc. (NASDAQ:OTLK) shares rose after the FDA accepted its resubmitted Biologics License Application for ONS-5010/LYTENAVA, aimed at treating wet age-related macular degeneration. The FDA has set a target action date of July 29, 2026, for this Class 1 review. ", "url": "https://www.investing.com/news/stock-market-news/outlook-therapeutics-stock-surges-on-fda-bla-resubmission-93CH-4745082", "source_name": "Investing.com", "published_at": "2026-06-16T14:09:14", "published_display": "16 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 93, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Announces FDA Acceptance of Resubmitted BLA for ONS-5010", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-announces-fda-acceptance-123508638.html", "source_name": "MT Newswires", "published_at": "2026-06-16T12:35:08+00:00", "published_display": "16 Jun 2026 12:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics: FDA accepts resubmitted BLA for ONS-5010 with PDUFA date July 29, 2026", "summary": "Outlook Therapeutics announced that the FDA has accepted its resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) for the treatment of wet Age-related Macular Degeneration (AMD). The FDA has designated this resubmission for a Class 1 review, setting a P", "url": "https://www.tradingview.com/news/tradingview:bd8a65baecb83:0-outlook-therapeutics-fda-accepts-resubmitted-bla-for-ons-5010-with-pdufa-date-july-29-2026/", "source_name": "TradingView", "published_at": "2026-06-16T13:09:14", "published_display": "16 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/LYTENAVA\u2122 (bevacizumab-vikg) as a Treatment for Wet AMD", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/outlook-therapeutics-announces-fda-acceptance-120200927.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T12:02:00+00:00", "published_display": "16 Jun 2026 12:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Stock After FDA Review Win Is The Valuation Case Already Priced In", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPTkVRLVQyZzB6WkhKRzV0bXNicUpBbjNjMW5DUUc4TENoRUpnNGdpQkVxNmdGbU5sd205c25LZWRMWW44WGVrejliZkFlS192OUo0OGVrTDBseklWNk92SGRHQXgwN1N4Rnp4TmVHcnNEdFlLYTdVXzQ1dkNqTE94S2RjUUc5NlE0UERFOW5OY3lFamRzRWJSR1N2alU?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Announces FDA Acceptance of", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAJBVV95cUxQUzB4OVZEUzA1QXdtZllGZUtDU0RWeTJVR05pcmpMZVhHOFU4UjJjZnl3V1NidDJsdW05LS1QZEVHWFhKZnRSekVCTWdTaVEtTnBCRHZrTnVPb0hhRjlsV0RrVkNiTVRXb1E5QkFkRkRmbk8tZkowSUY3Yk5pVU1YYU5ibEZVVERXd2JkYlBhU3JibGZaWDN4bW1KMWhlUkcyd2k5T3hKMHJrVWp5anBERmF4VVFUUlRGYkFlV0FUczNhY05vRkNkUERpT0c0ZU5lVXcydUFJdmJ5b1YyeGhjLUJISVIwbHJuN3E1M1ZrVmd3U0haWS00eVQ2OFpZb256bG91TGozS1M4b1R1bUZ1N0w2UFZxNExCWXNNNjFIVUZpQ3RZaXI1UmRnZ0YzMlpZbC1vUUFfRW1PLUpScnZCMFRjMU41RWg2RGtsSQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Is Up 60.7% After FDA Class 1 Review Acceptance For Lytenava", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Outlook Therapeutics (OTLK) Is Up 57.1% After FDA Validates LYTENAVA Efficacy and BLA Resubmission", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNUWdyS01vWE5rLUxwR1hYa3Z0T2pONmlMSmRxZW01MUJIT09NUVhDRXFJMmJUZVk0ZWl2eDdmT192ZDhoTC15ajUzT1RkQ29kNk9CYmVMc2lnTzhGNlBpVzh5OEVjdFRfdmVNbXZ2VUNfYURKSXlTX1FIYV9zYTZkNFpLdkdzT2pzODZLdnhfd2RSZmJxVEVSWm1jcWFlUHlfT1NR?oc=5", "source_name": "Market source", "published_at": "2026-06-14T07:00:00+00:00", "published_display": "14 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (OTLK) Stock After FDA Class 1 BLA Resubmission Is The Valuation Out Of Line", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity (NASDAQ:OTLK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQVlNFdXdmcDUxdF9yTHByaEVqTTRCbkM3akNmTldoZXdkNEt3eTVldXRSWEdnM2Z5Um1uTHN3S2EwVzVjWHhycWQ0cVJybGdyd19DUXpvWmVJSVg2bTdXYksxTHBWZWl3dEx3bHRoRk83X2J3WGstUkh6UV9oNUlwRWkySEwyMW5uUllSdHVSdE5oSDI5cGloV2lnd0JUWWVDdDRjdWtCcUNoZnpGQlBKYmphbHRLZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/outlook-therapeutics-resubmits-lytenava-biologics-131622271.html", "source_name": "MT Newswires", "published_at": "2026-06-01T13:16:22+00:00", "published_display": "01 Jun 2026 13:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPcTNvcTl0T0djVzlvdVhUZU5qNkwwTmJ6RlZDcVNZUkJ1eXFhNGlZTTdHNmtzbGo5N1JxSWUtT21LelB2MzNfUUN6d1RZM1BmdUpkQ19zWHJkNXRpWXVvTFR6M0dBazFMUmQ0S3NHUk1sT1kxRDl1akdzWm1XZTg1RTExUWtGSXQ5bUoteThuYWlrY0pNa3lOTVlBZ2RacFBMU1h1R2tIZ19ZSXdmYk1QNHpfLWQ?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (Nasdaq: OTLK) resubmits FDA BLA with 60-day review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOYW9vTU5FT0hqUzFzQUFWdzVFMFRrUTg1T0Mwb20zOEJZcGxEcldKUnNMU3FhZGhHaGlVNzlOUklBdGlxNHJfNHZ2dkdWdDJaNFVsZzlwclZtZUZNSk52T21jOTRfRVpWdFh4bG1hZUs2cHk5VTQ5Ni1rTTBTNlNFMDd3a3ZEQ0JzZHBKN0xTTHdGTTVBb3IzVG5MVDNvZ21JZ2hibzBoQ2NuWi1fTlZ2TW9VSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics (NASDAQ: OTLK) amends warrants and sells 8.54M shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOSGFqQ3dkMFlzYkg5VG42S1AyM3NJMmNDZFFwOXlkcW5yY2FNLUtNVzl3TnFzeUEydW81WjJId0l1a19XWkFoUl9IUEZKRFh3TkVLc0JaYUZhdjZSQUpLVFktelpGMV9CcVN3MUZudlkySmREa2hoUzB4bFFPcnV4OGxmeUI3eVYycVNueGZaNzJ2YXQyLThSYnBTX08wRFFpMjdnNWRUOFBHZzhPeXJibmZlWEFwS0NYNUtjcnRRWjdZSExBYXB2V3l3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics raises $5M from top holder, cuts warrant price to $0.5855", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxQRlJpZzFvcXFEZEpQamp6TTVZVHpZLXk5VUhfSDZaa2Q5V0x1Zjh3Vm9oeGRRcFpNamtUUGFQajB1a3ctdXJMbnU2eGQ2ZFNldFZVczlRLVJPNHpRQjFFZ1JvMXYzM0xLWU9sRkR0Y05TcUdiNGN4VHhHV2d4NURYVWljLWdxQnZwRmdOQm0wdHZfSkZITUlyRmpGTVJCV2I1Qm05SXdpWkVyeF83Rkk5YWxtQU9iVTBhNTBr?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA\u2122 (bevacizumab-vikg)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNUXcwMlhPQVh4T0Nha1F4c3dGSm9ZM2VMTEpVWnZ5SzU3NzQ2dnJxX2paQ3ZjT0xqU004VUZhSkxueFJxX294Zlo2T2RaOW5GQjNqM1diclNTTHNHUENyUHlDdjlxbE1aMWdEeU9jZDd6TlBLQ2N2ZHR1Z1FpTG5zRUNlc0prNHNyMWIyYzYtNWpoY0hfQTRBc3JPVTAxMWVNSlNlT1dSdWVfeEtOT2I3ZA?oc=5", "source_name": "Market source", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Reports Second Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNaVU5NkxxQmpVcTNvTG1EQkF4alk2VXFEencyY2Itdm9VUFF5bHhzNE5XbC0xbjVDVTJlV0h0VGVTT3hobGVjMkdqQ0xHYmFxYndCQ0V5Mzh2WmZCTC1ERnBDUTNWRFpna21CLXhPY1FFOU1GOFdyNGRVUkp1QnVMMFREclc4bVA4V1l3cENUeVBlRy1VSGhaM25vZXZ4TUMxMC1LYVBoWkk0RXV6MjVMZnVDcw?oc=5", "source_name": "VisionMonday.com", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAJBVV95cUxPYV8wZlE5Yl82Um9POEgzcVVxNE8xZ2JzTzNwQXkwZm9lOE5xVnI4Q3VLV0pqVHdac2gzbjFPV1VfclJCMGJidTFYZEg5UkxxVWVGY0NuQzZwb3NfRzFaLVJBOTAteDF2aml1OHJmOXhUR3A4dGpzN2ZCbFJJRHRZVEF3dlRkSk1NNkZhcXl3TzRJbXNDRUZVMXhFZ2ZFeXFyVE10MWUxS3ZmMDAzYm9sRmZlSFBKMUlhS3NzdlpkcDVvQkpjX3BCT3ExZmFIM1ZFY1RSOUZiaV9JamxSS1lwYThrVlA1UHd3M3VCV2JPRllBNmxQSjN6QmVYcVRXMXA4TEZKYlhuZUFiMXg2?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics files dispute resolution request with FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUWplNmg3aldZSk5OOFJJRDRWT3FfQVBjWThlVDhDZG5MVkUyWEhtMHBEZ2dBeVlMbDFlaXJLQjhITW1wSDhPdExuOFp4LW9HNnE4X19nVFhYUGdhOWRHWlk3WXczdEN0S0Vvd3F0aGhES2NQQTJNYndPX2VwUEdZYnhfRW94enI3Vm5PRGp2ZmtYTHdsN21ZTUpodTVOZHcyTFBSX0p6dG9HR21JQk9IMDYxRV9jYnc5WUhN?oc=5", "source_name": "Investing.com", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA\u2122 (bevacizumab-vikg) for the Treatment of Wet AMD", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPUWk4LXBvLWE1YmhMcXctTXZQVi1tWjRMZWdWdndrbmtVS2F6X1Z2ZTZ2NDBOSXc5ckVMTlAyNmNsWm1PZmNZTGp0dGs3QUxVREtNcGZKM0syYVdOSjFnQ01hY1pBR0R5TUVRVjMyMnZ6eFJMUnhqMm5VekZaeTg1SlowYXVkNjZSZzEyMjhGQ19hQQ?oc=5", "source_name": "Market source", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 60, "sentiment_summary": {"positive": 20, "negative": 4, "neutral": 36, "score": 58, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "guidance", "primary_label": "Guidance", "confidence": 87, "events": [{"event": "guidance", "label": "Guidance", "weight": 26.15, "count": 45}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}], "positive_events": 20, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.57, "latest_week": "2026-07-10", "one_week_move": 8.3, "four_week_move": 28.7, "twelve_week_move": 407.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.356275, "market_dynamics_buy_signal": false, "relative_strength": 24.745835, "fair_value_gap": -68.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.8547, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.3% over one week, +28.7% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Guidance", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 10}, {"label": "Stock Titan", "count": 5}, {"label": "StocksToTrade", "count": 4}, {"label": "Moomoo", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "GlobeNewswire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Guidance", "count": 45}, {"label": "Earnings", "count": 15}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Guidance", "tone": "neutral", "text": "87/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+8.3% over one week, +28.7% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "UnitedHealth\u2019s stock rallies on improved outlook for the year"}], "updated_at": "2026-07-16T11:43:00.585825+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}